Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Weeks Remain To Enter Global Generics & Biosimilars Awards 2020

Deadline Of 14 August For Entries Ahead Of Ceremony On 3 November

Executive Summary

Two weeks remain for companies to submit entries to the Global Generics & Biosimilars Awards 2020, with the entry deadline date of 14 August fast approaching ahead of the digital event on 3 November.

You may also be interested in...



Video Podcast: The Global Generics & Biosimilars Awards 2020

Hear all the details of the Global Generics & Biosimilars Awards 2020, now taking place on 3 November as a digital event, with a newly-extended entry deadline date of 14 August.

The Global Generics & Biosimilars Awards 2020 Is Going Digital

The Global Generics & Biosimilars Awards 2020 will take place on 3 November as a digital event, with a newly-extended entry deadline date of 14 August.

Teva Sees COVID Sales Correction

In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.

Topics

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel